Compile Data Set for Download or QSAR
Report error Found 4823 Enz. Inhib. hit(s) with Target = 'Kallikrein'
TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM50034582(Peptide boronate | CHEMBL2448441)
Affinity DataKi:  0.00490nMAssay Description:Binding affinity against kallikreinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetKallikrein-4(Human)
The University of Queensland

Curated by ChEMBL
LigandPNGBDBM50507481(CHEMBL4564063)
Affinity DataKi:  0.100nMAssay Description:Inhibition of KLK4 (unknown origin) expressed in sf9 cells using Ac-FVQR-pNA as substrate preincubated for 30 mins followed by substrate addition and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetKallikrein-4(Human)
The University of Queensland

Curated by ChEMBL
LigandPNGBDBM50507480(CHEMBL4543437)
Affinity DataKi:  0.130nMAssay Description:Inhibition of KLK4 (unknown origin) expressed in sf9 cells using Ac-FVQR-pNA as substrate preincubated for 30 mins followed by substrate addition and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357210(US10214512, Example 151-a)
Affinity DataKi:  0.160nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-7(Human)
University of Florida

Curated by ChEMBL
LigandPNGBDBM50612151(CHEMBL5287216)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of KLK7 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357151(US10214512, Example 110-a | (Z)-5-(3-Chloro-2,6-di...)
Affinity DataKi:  0.210nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357155(US10214512, Example 114-a | (Z)-5-(3-chloro-2,6-di...)
Affinity DataKi:  0.240nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357153(US10214512, Example 112-a | (Z)-5-(3-Chloro-2,6-di...)
Affinity DataKi:  0.260nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357026(5-(5-Chloro-2-(1H-tetrazol-1-yl)phenyl)-2-(24-((me...)
Affinity DataKi:  0.290nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357192(US10214512, Example 145-a)
Affinity DataKi:  0.300nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-4(Human)
The University of Queensland

Curated by ChEMBL
LigandPNGBDBM50507486(CHEMBL4566258)
Affinity DataKi:  0.300nMAssay Description:Inhibition of KLK4 (unknown origin) expressed in sf9 cells using Ac-FVQR-pNA as substrate preincubated for 30 mins followed by substrate addition and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetKallikrein-5(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50525914(CHEMBL4558285)
Affinity DataIC50: 0.316nMAssay Description:Inhibition of human recombinant 6His-Q-FLAG-tagged KLK5 expressed in baculovirus infected Sf9 insect cells using (Tos-Gly-Pro-Arg)2[R110].2TFA as sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357094(US10214512, Example 71)
Affinity DataKi:  0.330nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-5(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50513781(CHEMBL4466351)
Affinity DataKi:  0.340nMAssay Description:Inhibition of recombinant human KLK5 expressed in expressed in Pichia pastoris X-33 cells using Boc-VPR-MCA as susbtrate measured every 60 secs for 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357152(US10214512, Example 111-a | (Z)-5-(3-chloro-2,6-di...)
Affinity DataKi:  0.340nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357057(US10214512, Example 37)
Affinity DataKi:  0.360nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-14(Human)
Queensland University of Technology

Curated by ChEMBL
LigandPNGBDBM50124906(CHEMBL3623776)
Affinity DataKi:  0.400nMAssay Description:Inhibition of KLK14 (unknown origin) expressed in Sf9 cells using Ac-YANR-pNA substrate by spectrophotometry methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2016
Entry Details Article
PubMed
TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357188(US10214512, Example 143-b)
Affinity DataKi:  0.400nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619946(US20230295157, Example 270)
Affinity DataIC50: 0.400nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619925(US20230295157, Example 249 | N-(4-(2-((3S,8a*R)-7-...)
Affinity DataIC50: 0.400nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357166(US10214512, Example 122 | US10214512, Example 125)
Affinity DataKi:  0.430nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357143(US10214512, Example 102-a | (Z)-5-(5-Chloro-2-(dif...)
Affinity DataKi:  0.430nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-4(Human)
The University of Queensland

Curated by ChEMBL
LigandPNGBDBM50507482(CHEMBL4531700)
Affinity DataKi:  0.440nMAssay Description:Inhibition of KLK4 (unknown origin) expressed in sf9 cells using Ac-FVQR-pNA as substrate preincubated for 30 mins followed by substrate addition and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMed
TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357065((S)-2-(24-(((2-(tert-butoxy)ethoxy)carbonyl)amino)...)
Affinity DataKi:  0.440nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357110(9-(5-(5-chloro-2-(1h-tetrazol-1-yl)phenyl)-1-oxido...)
Affinity DataKi:  0.460nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357139(US10214512, Example 98-a | (Z)-5-(5-chloro-2-(1H-t...)
Affinity DataKi:  0.490nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM620044(US20230295157, Example 369 | N-(2-(2-((3S,8aR)-7-(...)
Affinity DataIC50: 0.5nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-5(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50525895(CHEMBL4447752)
Affinity DataIC50: 0.501nMAssay Description:Inhibition of human recombinant 6His-Q-FLAG-tagged KLK5 expressed in baculovirus infected Sf9 insect cells using (Tos-Gly-Pro-Arg)2[R110].2TFA as sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357206(US10214512, Example 150-a)
Affinity DataKi:  0.510nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357099(5-(3-chloro-2,6-difluorophenyl)-2-((5R,9S)-15-fluo...)
Affinity DataKi:  0.530nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357022(5-(5-Chloro-2-(1H-tetrazol-1-yl)phenyl)-2-((5R,9S)...)
Affinity DataKi:  0.590nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357137(US10214512, Example 96-a | (Z)-5-(3-chloro-2,6-dif...)
Affinity DataKi:  0.600nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619989(US20230295157, Example 313 | (3S)-3-(5-(3-Amino-1H...)
Affinity DataIC50: 0.600nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619910(US20230295157, Example 234)
Affinity DataIC50: 0.600nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619988(US20230295157, Example 312 | 5-(2-((3S)-7-(3-Chlor...)
Affinity DataIC50: 0.600nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357161(US10214512, Example 117)
Affinity DataKi:  0.650nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357174(US10214512, Example 130)
Affinity DataKi:  0.660nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM345078(US9783530, 23 | 2-(1-((4-Carboxyphenyl)amino)-1-ox...)
Affinity DataIC50: 0.700nMAssay Description:Kallikrein determinations were made in 50 mM HEPES buffer at pH 7.4 containing 150 mM NaCl, 5 mM CaCl2, and 0.1% PEG 8000 (polyethylene glycol; Fishe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/19/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619937(US20230295157, Example 261)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619914(US20230295157, Example 238 | 5-(2-((3*S,8aR)-7-(3-...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619983(US20230295157, Example 307 | N-(2-(2-((3S,8aR)-7-(...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619968(US20230295157, Example 292 | 5-(2-((3S,8aS)-7-(3-C...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619933(US20230295157, Example 257 | N-[2-[2-[(3S,8aR)-7-[...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619894(US20230295157, Example 218 | 4-(5-Chloro-2-((3S)-7...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619926(US20230295157, Example 250 | N-(4-(24(3S,8aS*)-7-(...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357055(US10214512, Example 35)
Affinity DataKi:  0.700nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM619987(US20230295157, Example 311 | 6-(2-((3S)-7-(3-Chlor...)
Affinity DataIC50: 0.700nMAssay Description:A fluorescence intensity (FLINT) based assay was used to monitor inhibition of human plasma kallikrein. The peptide substrate, Z-Gly-Pro-Arg-AMC (Pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357196(US10214512, Example 146-a)
Affinity DataKi:  0.710nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-1(Human)
Thrombosis Research Institute

Curated by ChEMBL
LigandPNGBDBM357168(US10214512, Example 124)
Affinity DataKi:  0.730nMAssay Description:The effectiveness of a compound of the present invention as an inhibitor of Kallikrein can be determined using a relevant purified serine protease, a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
US Patent

TargetKallikrein-5(Human)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50513784(CHEMBL4550494)
Affinity DataKi:  0.730nMAssay Description:Inhibition of recombinant human KLK5 expressed in expressed in Pichia pastoris X-33 cells using Boc-VPR-MCA as susbtrate measured every 60 secs for 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/21/2021
Entry Details Article
PubMed
Displayed 1 to 50 (of 4823 total ) | Next | Last >>
Jump to: